Fernando Agüero, Alejandro Forner, Andrés Valdivieso, Marino Blanes, Rafael Barcena, Christian Manzardo, Antoni Rafecas, Lluis Castells, Manuel Abradelo, Pilar Barrera‐Baena, Luisa González‐Diéguez, Magdalena Salcedo, Trinidad Serrano, Miguel Jiménez‐Pérez, José Ignacio Herrero, Mikel Gastaca, Victoria Aguilera, Juan Fabregat, Santos del Campo, Itxarone Bilbao, Carlos Jiménez Romero, Asunción Moreno, Antoni Rimola, José M.

Sang Gyune Kim, Joseph J. Larson, Ji Sung Lee, Terry M. Therneau, W. Ray Kim – 10 February 2017 – Nonselective beta‐blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end‐stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case‐control study in a cohort of liver transplant wait‐list registrants.

Elena Fernandez‐Sevilla, Marc‐Antoine Allard, Jasmijn Selten, Nicolas Golse, Eric Vibert, Antonio Sa Cunha, Daniel Cherqui, Denis Castaing, René Adam – 10 February 2017 – Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is widely considered as a terminal condition. Therefore, the role of surgery is uncertain in this case. The purpose of this study was to identify the prognostic factors of survival after post‐LT HCC recurrence and to evaluate the impact of surgery in this setting.

Ding Cao, Menghao Wang, Junhua Gong, Sidong Wei, Jianping Gong, Jinzheng Li – 10 February 2017 – Vascular endothelial growth factor (VEGF) promotes angiogenesis in vivo. We hypothesized that exogenous delivery of VEGF prior to bone marrow–derived endothelial precursor cell (EPC) transplantation may improve orthotopic liver transplantation (OLT)–induced hepatic ischemia/reperfusion injury (HIRI).

John R. Senior – 9 February 2017

Benjamin Cadier, Julie Bulsei, Pierre Nahon, Olivier Seror, Alexis Laurent, Isabelle Rosa, Richard Layese, Charlotte Costentin, Carole Cagnot, Isabelle Durand‐Zaleski, Karine Chevreul, the ANRS CO12 CirVir and CHANGH groups – 8 February 2017 – Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence‐based monitoring. The objective of this study was to estimate the cost‐effectiveness of complying with HCC screening guidelines.

Marcin Krawczyk, Monika Rau, Frank Grünhage, Jörn M. Schattenberg, Heike Bantel, Anita Pathil, Münevver Demir, Johannes Kluwe, Tobias Boettler, Andreas Geier, Frank Lammert, NAFLD Clinical Study Group (NAFLD CSG) – 8 February 2017

Cybele Lara R. Abad, Brian D. Lahr, Raymund R. Razonable – 8 February 2017 – The epidemiology of infections after living donor liver transplantation (LDLT) is limited. We aimed to study the epidemiology and risk factors of infections after LDLT. The medical records of 223 adult patients who underwent LDLT from January 1, 2000 to August 31, 2015 were reviewed for all infections occurring up to 1 year. We estimated the cumulative incidence of infection using the Kaplan‐Meier product limit method. Risk factors were analyzed with time‐dependent Cox regression modeling.

Solène Denolly, François‐Loïc Cosset – 8 February 2017

Min Woo Lee, Steven S. Raman, Nazanin H. Asvadi, Surachate Siripongsakun, Robert M. Hicks, Jeffrey Chen, Akeanong Worakitsitisatorn, Justin McWilliams, Myron J. Tong, Richard S. Finn, Vatche G. Agopian, Ronald W. Busuttil, David S.K. Lu – 7 February 2017 – In a long‐term (10‐year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post‐LT tumor recurrence, and long‐term intention‐to‐treat, disease‐specific survival (DSS).